#+OPTIONS: org-inline-image-overlays:t org-image-actual-width:nil
#+ATTR_HTML: :width 40px
* antibacterial targets :l:
** Cell Wall Biosynthesis
*** Beta-lactam antibiotics
**** Why do β-lactam antibiotics inhibit penicillin-binding proteins (transpeptidase)?
(D-Ala)₂ looks a lot like penicillin, so PBP-Serine-OH reacts with penicillin instead of (D-Ala)₂ on the growing peptidoglycan polymer. β-lactam antibiotics irreversibly inhibit PBP.
**** β-lactamase hydrolysis of penicillin
β-lactamase-Ser-OH opens β-lactam ring at carbonyl
**** resistance
***** causes
production of β-lactamase by bacteria
***** mechanism
β-lactamase hydrolyzes the β-lactam ring
**** SAR
***** overcoming resistance
- add bulky functional groups to the acyclic amide to sterically inhibit β-lactamases
- electron withdrawing group to acyclic amide
***** acid stability
- electron withdrawing group as substituent to acyclic amide
- adding acid stability allows the drug to have good oral bioavailability
***** both acid stability and β-lactamase resistance
sterically bulky /and/ electron withdrawing group substituted on the acyclic amide
**** classes :l:
***** Penicillins
****** types by structure :l:
******* methicillin
******* isoxazole
******* ureidopenicillin
******* acidic penicillin
******* amino penicillin
****** Penicillin G/V
******* Pen G IV
******** common use
CNS manifestations of syphillis
******** syphillis—causative agent
Treponema pallidum
******* Pen G IM PCNs
******** common use
major Strep infections
******* Pen V PO
- strep throat
- some dental infections
****** semi-synthetic penicillins :l:
******* Naficillin
******** indication
nosocomial MSSA
******* Methicillin
******* Oxacillin
stable toward acid and β-lactamase
Bactocil
******** brand
******* Dicloxacillin
stable toward acid and β-lactamase
******** brand
- Dycill
- Pathocil
******* Amoxicillin/Ampicillin
******** coverage
- Strep. pneumo. and Intermediate S. pneumo in higher dosage
******** Ampicillin
- DOC for listeria
****** Acidic penicillins :l:
******* Ticarcillin
******** coverage
- Pseudomonas
- Gram-
****** “isoxazole penicillins”
- oxacillin
- dicloxacillin
****** Ureidopenicillins
******* Piperacillin
******** spectrum
- Pseudomonas aeruginosa
- Enterococcus
****** Aminopenicillins
******* ampicillin
******** indication
drug of choice for /Listeria/ infections
******* amoxicillin
******** prodrug
form with unionized amino groups, which would be ionized at physiological pH
****** MSSA
sensitive staph aureus (MSSA); this is /not MRSA/
******* practical uses
bactericidal against staph
****** questions
******* PO only?
- Penicillin V
******* IV only?
- Timentin
- Zosyn
****** physiochemical properties
******* acid-base attacks
acid-catalyzed ring opening of the strained Penam nucleus
******* pH environment
- Stable between 6-7.2
- Do not place in highly acidic or basic environment
****** combinations :l:
******* Amoxicillin + Clavulanic acid
******* Ticarcillin + Clavulanic Acid
******* Ampicillin + Sulbactam
******* Piperacillin + Tazobactam
***** Cephalosporins
****** general structure
[[./cephalosporin_general_structure.png]]
****** avoid with TPN or divalent metal ions
Ceftrioxone (Rocephin)
****** SAR
******* free carboxylic acid at C2
- must be present for antibacterial activity
- prodrugs formed by making an ester with the carboxylic acid at C2
******* 
****** 1st generation
******* Cefazolin
******** brand
Ancef
******** ROA
IV
******** indication
prophylaxis of Staphylococcus infection, esp. in surgery
******** spectrum
Gram-(+)
******* Cephalexin
******** brand
Keflex
******** ROA
PO
******** spectrum
- Gram-(+)
- modest activity against Gram-(-)
******* Cefadroxil
******** ROA
PO
******* Cephalothin
******** ROA
IV
****** 2nd generation
******* Cephamycins
******** common structural feature
7-methoxy group off the 3-cefem nucleus
******** spectrum
- certain anaerobic bacteria
- Bacteroides fragilis
******** drugs :l:
********* cefoxitin
********* cefotetan
********* cefmetazole
******* NON-cephamycins
******** indications
- COPD/bronchitis
- H. influenzae
******** drugs :l:
********* cefaclor
********** brand
Raniclor
********** ROA
PO
********* cefprozil
********** brand
Cefzil
********** ROA
PO
********* cefonicid
********* cefuroxime
********* cefoxitin
****** 3rd generation
******* common structural feature
2-amine-1,3-thiazole ring
******* ROA
parenteral
******* drugs
******** IV :l:
********* Ceftriaxone 
********** brand
Rocephin
********** DOC for
Neisseria meningitis
********** usage
don’t administer within 24h of calcium products e.g. TPN
********* Cefotaxime
********** brand
Claforan
********* Ceftazidime
********** brand
- Fortaz
- Tazicef
********** coverage
- potent inducer of β-lactamase, especially in Enterobacter
- Pseudomonas
- Gram-(-) rods
******** “super hero gen”
********* ceftazidime/avibactam
********* ceftolozane/tazobactam
******** PO :l:
********* Cefixime
********* Cefdinir
********* Cefditore
********* Cefixime
********* Ceftibute
********* Cefoperazone
********* Ceftizoxime
********** brand
Cefizox
****** 4th generation
******* drugs
******** Cefepime
********* ROA
Cefepime
********* brand
Maxipime
****** 5th generation
******* drugs :l:
******** Ceftaroline
********* brand
- Teflaro
- Fosamil
********* ROA
IV
********* spectrum
- MRSA
- S. pneumoniae
- K. pneumoniae
- E. coli
***** Carbapenems
****** cilastin
inhibits renal dehydropeptidase-1, which hydrolyzes the β-lactam ring of imipenem
******* Primaxin
Imipenem + Cilastin
****** drugs :l:
******* Imipenem
******* Meropenem
******* Doripenem
******* Ertapenem
******** brand
Invanz
****** indications
- Basically covers everything (including anaerobes, atypicals, nasty GNRs, PA, etc).
- Ertapenem (Invanz) barely covers anything
****** non-indications
- MRSA
***** Carbacephems
***** Monobactams
****** drugs :l:
******* Aztreonam
******** ROA
IV
******** coverage
- Gram-
**** allergy
***** structures that cause reactivity
- β-lactam ring structure
- S on the β-lactam ring
- R1 group side chains
**** structures
***** [[./isoxazole_ring.png]]
isoxazole ring
***** [[./ampicillin.png]]
ampicillin
***** [[./cephalosporin_core_structure.png]]
cephalosporin
***** nuclei of each class
****** [[./cefem_nucleus.png]]
cefem nucleus
****** [[./penam_nucleus.png]]
penam nucleus
****** [[./monobactam_nucleus.png]]
monobactam nucleus
*** Glycopeptide :l:
**** Vancomycin
*** Glycolipopeptide :l:
**** Telavancin
**** Oritavancin
**** Dalbavancin
*** Miscellaneous
**** Cycloserine
***** side effects
CNS disturbances
***** MOA
- inhibits 2 key enzymes
  - D-alanine racemase
  - D-alanine synthase/ligase
- blocks peptidoglycan cross linking of the myobacterial cell wall
***** indication
TB infections
***** SAR
rigid analog of D-alanine
**** Isoniazid
***** indication
TB infections
**** Ethionamide
**** Ethambutol
**** Teicoplanin
*** Lipopeptides :l:
**** Daptomycin
***** MOA
- lipophillic decanoyl side chain inserts into bacterial cell membrane
- bactericidal
***** indications
**** Polymixins
***** MOA
- detergent-like effect
- loss of cell membrane integrity
- bactericidal
***** indications
- IV agent used to kill nasty infections
- Gram(-) bacteria
**** Bacitracin
***** spectrum
Gram(+)
***** formulation
- topical
- only available in combinations
  - with Polymyxin B (Polysporin™)
  - with Polymyxin B and Neomycin (Neosporin®)
**** Colistin
** Cytoplasmic Membrane 
** DNA Biosynthesis
*** fluroquinolones
**** MOA
- inhibits topoisomerase II (DNA gyrase), which replicates, transcribes, and repairs bacterial DNA
- inhibits topoisomerase IV, which partitions DNA during cell division
- bactericidal
- concentration-dependent
**** structure
[[./fluroroquinolone_keto_enol_structure.png]]
**** SAR
****** CNS side effects
caused by a basic ring system substituent on C-7—pyrrolidine, piperazine, substituted piperazine, bicyclic ring system
****** C-3
must have a carboxylic acid at C-3
****** N-1
1,4-dihydroquinolone portion is essential because it freezes the drug in the correct keto-enol tautometer
****** chelation
- carboxylic acid at C-3
- keto at C-4
chelates divalent and trivalent cations; decreases oral bioavailability
****** fluorine subsitutent
******* at C-6
- good activity against Gram(-) bacteria
- broad spectrum activity
******* at C-6 and C-8
- improves drug absorption and half-life
- increases drug-induced photosensitivity
**** drugs :l:
***** levofloxacin
****** brand
Levaquin
****** spectrum
- Gram(-)
- atypicals
- S. pneumoniae
- sensitive Staph.
***** gemifloxacin
****** indications
- very poor activity against Pseudomonas aeruginosa
****** spectrum
respiratory pathogens
***** moxifloxacin
****** brand
Avelox
****** indications
- respiratory pathogens, including S. pneumoniae
****** non-indicaations
UTIs
***** ciprofloxacin
****** brand
Cipro
****** spectrum
- enteric Gram(-) rods
- doesn’t cover
  - S. pneumoniae
****** indications
anthrax
****** non-indications
S. pneumoniae
***** norfloxacin
****** brand
Noroxin
****** indication
UTIs only
****** spectrum
Gram(-)
**** warnings
ALL QUINOLONES SHOULD NOT BE CO-ADMINISTERED WITH TPN AND DIVALENT METAL IONS
*** metronidzole
*** nitrofurantoin
** folate synthesis inhibitors
*** dapsone
*** trimethoprim/sulfamethoxazole
** DNA-dependent RNA Polymerase
** RNA inhibitors :l:
*** rifamycins :l:
**** rifampin
**** rifabutin
**** rifapentine
** Protein Biosynthesis Inhibitors
*** 30S :l:
**** tetracyclines
***** SAR
chelation of divalent and trivalent caations occur at C-{10, 11, 12}
***** drugs :l:
****** tetracycline
******* indication
skin and skin-structure infections in people ≥18 yo
******* class
glycylcycline
******* spectrum
- MSSA and MRSA
- Enterococcus faecalis (vancomycin-susceptible strains)
- Streptococcus species
- E. coli
- Bacteroides fragalis (an anaerobe)
****** doxyycline
******* ROA
- PO
- IV
******* spectrum
- aytpicals
  - Chlamydia
  - Chlamydophilia
  - M. pneumoniae
- tick borne diseases
  - Ehrlichia
  - Ricksettsoses
  - Vibrio cholerae, V. vulnificus
  - community associated MRSA
  - S. pneumniae
  - anthrax
****** minocycline
******* adverse effects
- dizziness
- vertigo
******* spectrum
community associated MRSA
******* indicaitons
- acne
- dental work
****** tigecycline
******* brand
Tygacil
******* ROA
IV only
****** ervacycline
****** omadacycline
***** adverse effects
- discoloration of developing
- CNS effects because its high lipid solubility allows it to enter CNS
***** mechanisms of resistance
- efflux of antibiotic from microbe
- decreased penetration into microbe
- bacterial production of a ribosome protective protein
**** amingolycosides
***** MOA
- concentration-dependent bactericidal killing
- binds to 30S ribosomal subunit, intefering with protein synthesis
***** mechanisms of resistance
- phosphorylation of hydroxyl groups
- adenylation of hydroxyl groups
- acetylation of amino groups
***** drugs :l:
****** plazomicin
****** gentamicin
******* spectrum
- Gram-(-)
- P. aeruginosa
****** tobramycin
******* spectrum
P. aeruginosa
****** amikacin
******* spectrum
- high activity on nasty GNRs
- P. aeruginosa
****** streptomycin
***** toxicity
- nephrotoxicity
- ototoxicity
- neurotoxicity
***** combination
used /synergistically/ in combination with beta-lactam antibiotics or glycopeptides
*** 50S :l:
**** macrolides
***** drugs :l:
****** erythromycin
******* disadvantages
- acid catalyzed degradation in the stomach
- less than desirable bioavailability
- side effects
  - GI
  - hepatotoxicity
- significant resistance
****** clarithromycin
******* ROA
PO only
****** azithromycin
****** telithromycin
******* brand
Ketek
******* spectrum
macrolide-resistant pathogens including S. pneumoniae
******* toxicity
- hepatotoxicity
- prolongation of QTc interval
******* SAR
C-6 methoxy improves acid stability
****** fidaxomycin
******* brand
Dificid
******* spectrum
- narrow
- mainly used against C. dificile
***** structure
[[./macrolide_structure.png]]
***** MOA
- bacteriostatic
- blocks translation by binding to 50S ribosomal subunit
***** non-indications
- respiratory tract infections---use alternative agents for Moraxella, atypical pneumonia organisms (Mycoplasma, Chlamyida, Legionella)
- use alternative agents for S. pneumoniae---erythromycin is resistant
***** indications
- acne
- dental infections
- H. influenzae infections
***** SAR
****** gut
intramolecular nucleophillic attack by hydroxyl on the carbonyl group results in an inactive drug
**** lincosamide
***** drugs :l:
****** clindamycin
******* brand
Cleocin
******* spectrum
- Gram-(+)
- MRSA
- Strep., esp. in patients allergic to beta-lactams
**** streptogramins
***** drugs :l:
****** quinupristin/dalfopristin
******* ROA
IV
******* spectrum
- MRSA
- VRSA
- VRE faecium---not /faecalis/
***** spectrum
Gram-(+)
**** oxazolidinones
***** drugs :l:
****** linezolid
******* brand
Zyvox
****** tedizolid
******* brand
Sivextro
***** warnings
- therapy more than 2 weeks increases risk of thrombocytopenia/pancytopenia
- not for use in endocarditis/endovascular infections
**** nitro compounds
***** drugs :l:
****** nitrofurantoin
******* brand
- Macrodantin
- Macrobid
****** metronidazole
******* brand
Flaygyl
******* disulfiram-like reaction
abstain from alcohol during therapy for 72 hours post-therapy---metronidazole inhibits aldehyde dehydrogenase
******* indications
- Bacterioides fragilis
- Clostridium difficile colitis
- Heliobacter pylori
- Trichomonas vaginalis
- Amebiasis
- Giardiasis
****** tinidazole
******* brand
Tindamax
** Tetrahydrofolic Acid
* therapeutics
** bactericidal drugs
- Vancomycin
- Fluoroquinolones
- Penicillin
- Aminoglycosides
- Cephalosporins
- Metronidazole
** bacteriostatic drugs
- Erythromycin
- Clindamycin
- Sulfamethoxazole
- Trimethoprim
- Tetracyclines
- Chloramphenicol
** lower respiratory infections
*** community acquired pneumonia
**** diagnostics :l:
***** chest radiography (CXR)
- most common
- looks for
  - infiltrate
  - patchy consolidation
***** pretreatment blood cultures
test for etiology
***** biomarkers
- C-reactive protein (CRP)
- procalcitonin (PCT)
**** pathogens
- Chlamydophilla pneumoniae
- Haemophilus influenzae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Streptococcus cpneumoniae
**** assessment
***** CURB-65
- confusion : 1 point
- BUN ≥20 mg/dL : 1 point
- RR ≥30 bpm : 1 point
- SBP <90 mm Hg or DBP ≤60 mm Hg : 1 point
- age ≥65 : 1 point
**** treatment
***** categories
****** no antibiotic use in the past 3 months and previously healthy
- macrolide
- doxycycline
****** risk factors for drug-resistant /S. pneumoniae/ or comorbidities
- β-lactam + { macrolide, doxycyline }
- respiratory quinolone monotherapy
***** based on CURB-65 score
- 0-1: monotherapy in patients without cormobodities
- 2: combination antibiotics or quinolone; inpatient, no ICU admission
- 3-4: beta-lactam + {macrolide, quinolone}; also requires inpaatient ICU admission
*** hospital acquired pneumonia
**** goal trough of vancomycin
15-20 mcg/mL
**** causative agents
- Pseudomonas sp.
- Acinetobacter sp.
- Escherichia sp.
- Klebsiella sp.
- Staphylococcus aureus
* no coverage against strep pneumoniae
Cipro
* moxifloxacin
not a drug for UTIs
* gastrointestinal infections
** dystentery
- Y. enterocolitica 
- EHEC (Enterohemorrhagic E. coli)
- Campylobacter spp.
- Salmonella spp.
- Shigella spp.
** Guillain-Barre syndrome
C. jejuni
** HUS
*** acronym
hemolytc uremic syndrome
*** increases HUS risk
use of a fluoroquinolone or Bactrim may increase the risk of HUS by increasing production of Shiga-like toxin
** severe diarreha
>8 stools per day
** infectious diarrhea
*** treatment
**** fluid and electrolyte replacement
***** oral rehydration
Pedialyte, Rehydralyte, Infalyte, Oralyte, WHO formula
***** severe dehydration
****** definition
≥10% body weight loss
**** bismuth subsalicylate
***** brand
Pepto-Bismol
***** warnings
avoid in children because it may cause Reye’s syndrome
***** dosing‘
- 30 mL (2 tabs) q30-60min
- max 8 doses q24h
**** when antibiotic therapy recommended
- Severe diarrhea 
- Moderate-to-severe cases of traveler’s diarrhea
- Most cases of febrile dysenteric diarrhea
- Culture-proven bacterial diarrhea in high-risk patients
- Severe cases of cholera 
- ETEC 
- Pregnancy
- Immunocompromised patients
- Prolonged illnesses 
- Infants <3 months old
- Patients with fever and signs and symptoms of sepsis
**** watery diarrhea
***** ETEC
- Ciprofloxacin (Cipro) 750 mg PO x1
- azithromycin (Zithromax) 1000 mg PO OR 500 mg QD x3d
- rifamixin 200 mg PO TID x3
***** Vibrio cholerae
doxycycline 300 mg PO x1
**** dysenteric diarrhea
***** Campylobacter sp.
- azithromycin 500 mg PO QD x3d
- erythromycin 500 mg PO q6h x3d
***** Salmonella nontyphoidal, Shigella sp., Yersinia sp.
- Ciprofloxacin 750 mg PO QD
- Levofloxacin 500 mg PO QD
** traveler’s diarrhea
*** prophylaxis :l:
**** Bismuth subsalicyclate
***** brand
Pepto-Bismol
***** dosage
524 mg (2 tabs or 2 tbsp) PO QID
**** fluoroquinolones
**** doxycyline
**** azithromycin
**** rifaximin
200 mg pO TID only for Latin America and Africa
***** spectrum
only effective against E. coli
*** treatment
**** loperamide
***** brand
Immodium
***** indication
symptomatic relief
***** dose
4 mg x1 then 2 mg each subsequent stool; max 16 mg/day
**** empiric treatment
***** fluroquinolones
****** ciprofloxacin
****** levofloxacin
****** norfloxacin
800 mg PO x1d or 400 mg PO BID x3d
***** azithromycin
****** dose
1 g PO x1 or 500 mg PO QD x3
****** indication
South and Southeast ASia
***** Rifaximin
****** dose
200 mg PO TID x3
****** indication
Mexico and Jamaica
** food poisoining
*** Enterotoxigenic poisonings
- Bacillus cereus
- Clostridium botuilism
- Clostridium perfringens (type A)
- Staphylococcus aureus
* intra-abdominal infections
** pathophysiology
bacterial entry into and collections in the peritoneal or retroperitoneal spaces
*** pathogens to cover
**** peritonitis
***** primary
everything except anaerobes (i.e., Bacteroides)
*** TODO
cover e. coli for...
*** 
** peritonitis
*** primary
An infection of the peritoneal cavity without an evident source in the abdomen
**** causes
***** cirrhosis
alcohol abuse
***** ascites
- CHF
- malignancy
- systemic lupus erythematosus
- nephrotic syndrome
- hepatitis
***** bacterial
****** cirrhotic ascites
E. coli
****** peritoneal dialysis
- Gram-(+) coagulase-negative Staphylococci
  - S. aureus
  - S. streptococci
  - S. enterococci
- Gram-(-)
  - E. coli
  - Klebsiella spp.
  - Pseudomonas spp.
**** signs and symptoms
**** lab tests
- elevated WBC count
- ascitic fluid analysis
  - leukocyte count >250 PMNs/mm^3
  - gram stain
*** dialysis
staph and strep
*** secondary
A focal disease process in the abdomen
**** causes
- mechanical GI problems
- vascular causes
- trauma
- intraoperative events
- leakage from GI anastomosis
**** lab tests
- CBC with differential---in order to see bands
- Hct and BUN
*** tertiary
Infection that persists/ recurs 48h after adequate management of 1° or 2° peritonitis
** treatment
*** community-acquired complicated intra-abdominal inffections
**** mild-to-moderate infections
***** single agent
- Cefoxitin
- Moxifloxacin 400mg IV q24h
- Ertapenem 1g IV q24h
***** combination agents
- {cefalozin, cefuroxime, ceftriaxone, cefotaxime} + metronidazole 500mg IV q8h
- {ciprofloxacin 400mg IV q12h, levofloxacin 750mg IV q24h} + metronidazole 500mg IV q8h
**** high risk or high severity
***** single agent
- piperacillin-tazobactam
- carbapenem with Pseudomonas activity:
  - imipenem-cilastin
  - meropenem 1g IV q8h
  - doripenem
***** combination agents
- cefepime 2g IV q8-12h
- ceftazidime 2g IV q8h + metronidazole 500mg IV q8h
- {ciprofloxacin 400mg IV q12h, levofloxacin 750mg IV q24h} + metronidazole 500mg IV q8h
*** healthcare-acquired complicated intra-abdominal inffections
**** single agent
- piperacillin-tazobactam 3.375 IV q6h
- carbapeem with Pseudomonas activity
  - imipenem-cilastin
  - meropenem 1g IV q8h
  - doripenem
**** combination agents
- {Cefepime 2g IV q8-12h, ceftazidime 2g IV q8h} + metronidazole 500mg IV q8h
- β-lactam allergy: Aztreonam (Azactam) + vancomycin 15mg/kg IV q12h + metronidazole 500mg IV q8h
*** primary peritonitis
vancomycin + {cefepime-ceftazidime, imipenem-cilastin} for at least 1 week after the dialysate fluid is clear
*** acute cholecystitis and cholangitis
#+ATTR_ORG: :width 700
[[./treatment_for_acute_cholecystitis_and_cholangitis.png]]
*** anti-MRSA therapy
vancomycin

Empiric coverage for nosocoial intra-abdominal infectious patients known to be colonized or at risk of a MRSA infection due to significant, maybe failed, antibiotic exposure
*** use of aminoglycosides
**** reserved for specific patients
- infections due to multidrug-resistant Gram-(-) pathogens
- IgE-mediated allergic reactions
**** extended interval dosing
reasons for which are...
- concentration dependent killing
- long postantibiotic effect for Gram-(-) bacilli
* urinary tract infections
** causative organisms
*** community-acquired :l:
**** E. coli
Gram-(-)
**** Staphylococcus saprophyticus
Gram-(+)
**** Proteus mirabilis
Gram-(-)
**** Klebsiella pneumoniae
Gram-(-)
**** Enterococcus faecalis
Gram-(+)
*** nosocomial-acquired :l:
**** E. coli
**** Enterococcus spp.
**** Klebsiella pneumoniae
**** Enterobacter spp.
**** Serratia spp.
**** Staphylococcus aureus
**** Pseudomonas aeruginosa
**** Candida spp.
** lab tests
*** urinalysis
1. midstream clean-catch method---preferred method
2. catheterization
3. suprapubic bladder aspiration
**** normal values
***** leukocytes
0-5 cells/mm^3
***** erythrocytes
0-2 cells/mm^3
***** crystals/casts
None
***** bacteria
None
***** epithelial cells
0-2 cells/mm^3
***** pH
4.5-8
***** specific gravity
1.003-1.03
** significant bacteriuria
*** females
*** males
*** catheterized patients
** cystitis
- lower urinary tract infection
- inflammation of the bladder, urethra, prostate, and epididymis
*** signs and symptoms
- Dysuria
- Frequency
- Urgency 
- Nocturia 
- Suprapubic heaviness 
- Hematuria (gross) 
- Fever usually absent 
*** treatment of complicated cystitis
*** treatment of acute uncomplicated cystitis
** pyelonephritis
- upper urinary tract infection
- inflammation of the kidney from infection
*** treatment of acute pyelonephritis
*** signs and symptoms
- Flank pain 
- Fever 
- Nausea
- Vomiting 
- Malaise 
- Hematuria (gross)
** treatment
*** relapse
*** recurrent
*** pregnancy
*** prostatitis
** drug-drug interactions
** questions
*** A patient diagnosed with a nosocomial-acquired UTI should be empirically treated for what microorganism? 
- Enterococcus faecalis 
- +Legionella pneumophila+
- +Streptooccous pyogenes+
- +Staphylococcus saprophyticus+
